Arrhythmias & electrophysiologyCohort study
Modern subcutaneous implantable defibrillator therapy in patients with cardiomyopathies and channelopathies: data from a large multicentre registry
- Prospective registry study
- multicentre
- consecutive patients
Authors' conclusion
Modern S-ICDs may be a valuable alternative to transvenous ICDs in patients with cardiomyopathies and channelopathies. Our findings suggest that modern S-ICD therapy carries a low rate of IS.
Study context
- Population
- Patients with cardiomyopathies or channelopathies undergoing modern subcutaneous ICD (S-ICD) implantation, January 2016 to December 2020, followed up until December 2022of 1338 S-ICD implantations
- Participants
- 628 patients
- Exposure
- Cardiomyopathies vs channelopathies
- Outcome
- Inappropriate shocks (IS)
- Follow-up
- 12 months
Main finding
As reported in the abstract
Inappropriate shocks
P = 0.032
Observational data: associations, not effects.
Further findings
| Outcome | Cardiomyopathies | Channelopathies |
|---|---|---|
| Appropriate shocks · 12 months | 2.3% (95% CI 1.1–4.1) | 2.1% (95% CI 0.6–5.3) |
- Appropriate shocks: P = 1.0
Inappropriate shocks (IS) over follow-up · median follow-up 43 months
- No significant differences
- HR: 0.76; 95% CI: 0.45-1.31; P = 0.351
Need for pacing
- Need for pacing low
- 0.8%
Safety
| Outcome | Cardiomyopathies | Channelopathies | P value |
|---|---|---|---|
| Device-related complications · 12 months | 0.9% (95% CI 0.3–2.3) | 3.2% (95% CI 1.2–6.8) | P = 0.074 |
Device-related complications · 12 months
- No significant differences over the entire follow-up
Original publication
Modern subcutaneous implantable defibrillator therapy in patients with cardiomyopathies and channelopathies: data from a large multicentre registry. Europace. Published 3 August 2023. doi:10.1093/europace/euad239
Summarised from the published abstract; every number is checked against it